Biosynthetic proteins show promise as SARS-CoV-2 antivirals targeting spike protein

Researchers developed an αRep series specific to the RBD of the SARS-CoV-2 S, which could easily adapt to work stably against SARS-CoV-2 variants at a low cost.

Related Keywords

,Image Credit ,Coronavirus Disease Covid 19 ,Protein ,Cars ,Ars Cov 2 ,Spike Protein ,Ce2 ,Ngiotensin ,Ngiotensin Converting Enzyme 2 ,Antibodies ,Coronavirus ,Covid 19 ,Nzyme ,Eceptor ,Espiratory ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,Virus ,